Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Teva and Oncogenex begin second phase III custirsen trial in prostate cancer

Oct. 4, 2010

Astellas Pharma patents new 17-beta-HSD 5 inhibitors

Oct. 1, 2010

Unibioscreen claims novel cardiotonic steroid derivatives

Oct. 1, 2010

Medivation and Astellas begin phase III MDV-3100 trial in advanced prostate cancer

Oct. 1, 2010

Cylene begins phase I trial of CX-4945 in multiple myeloma

Oct. 1, 2010

Homopiperazine acethydrazide derivatives patented as oncolytic agents

Sep. 30, 2010

Genta initiates new phase II trial of tesetaxel in advanced bladder cancer

Sep. 30, 2010

Pfizer discontinues phase III Sutent trial in castration-resistant prostate cancer

Sep. 30, 2010

New phase II OGX-427 trial begins in metastatic prostate cancer

Sep. 30, 2010

Dana-Farber Cancer Institute and sanofi-aventis collaborate on oncology targets

Sep. 30, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...